Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Implantable Drug Delivery Devices Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.
The implantable drug delivery devices industry has reported enduring growth, showcasing a remarkable increase from USD 19.66 billion in 2023 to an anticipated USD 21.21 billion in 2024, with a compound annual growth rate (CAGR) of 7.8%. This growth trajectory reflects a burgeoning recognition of preventive healthcare and a consistent rise in the aging population across the globe.
In-Depth Market Insights Untangled in a New Comprehensive Study
This meticulously researched market report embarks upon a panoramic examination of the implantable drug delivery devices sector, laser-focusing on key attributes such as market size, regional economic contributions, and pivotal industry players. The report navigates through an array of factors enhancing the market's framework and demystifies the innovative landscapes that set the stage for future growth.
Technological Innovations to Shape the Future of Drug Administration
The industry is heralding a new epoch as tailored drug delivery systems entwinewith minimally invasive surgical procedures, enhanced by the convergence of technology with healthcare services such as telemedicine, 3D printing and AI-powered drug dosing. As the healthcare expenditure skyrockets, the market is priming itself for an 8.1% CAGR from 2024 to 2028, ultimately achieving a valuation of USD 28.91 billion.
- Rise in Chronic Disease Incidence Drives Market Expansion
- Product Innovation Focused on Non-Invasive Delivery Methods
- Market Leaders Engage in Strategic Collaborative Ventures
Profiling a diverse coterie of medical fields ranging from cardiovascular treatments to oncology, the report zooms in on the array of implantable drug delivery devices, including contraceptive and spinal implants, bioabsorbable stents, and infusion pumps. With ground-breaking advancements at their core, these devices are fast becoming staples in the fight against chronic illnesses.
A selection of companies mentioned in this report includes
- AbbVie Inc.
- Bayer HealthCare
- Medtronic Inc.
- Nucletron
- Boston Scientific Corporation
- Abbott Laboratories
- Bausch and Lomb Inc.
- Merck & Co. Inc.
- Genentech Inc
- EyePoint Pharmaceuticals Inc.
- DSM Biomedical
- Delpor Inc.
- Teleflex Incorporated
- 3M Company
- Biotronik Inc.
- Alcon Inc.
- Terumo Corporation
- Endologix Inc.
- TransEnterix Inc.
- China Grand Pharmaceutical and Healthcare Holdings
- Innocoll Biotherapeutics
- Atossa Therapeutics Inc.
- Intersect ENT
- Microchips Biotech
- Theradaptive Inc.
- CollPlant
- Intarcia Therapeutics
- Glaukos Corporation
For more information about this report visit https://www.researchandmarkets.com/r/g51k83
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
